Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

Qu Biologics Inc. announced a new collaboration with Associate Professor Jonas Fuxe and his research team at the Karolinska Institute in Stockholm, Sweden, to characterize the molecular targets of Qu’s Site Specific Immunomodulator therapy by assessment of tissue biopsies from the gastrointestinal tract of patients with moderate-to-severe Crohn’s disease who experienced histological healing upon treatment.